Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.80 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.80 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA3 | P07451 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | CA4 | P22748 | 1/20 | 0.57 |
| ▸ | CA6 | P23280 | 1/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5071011 | 0.97 | PTGS2 (0.79) | PTGS2NR4A2MT-CO2PTGS1LMNA | |
| SCHEMBL8894931 | 0.96 | PTGS2 (0.77) | PTGS2NR4A2MT-CO2PTGS1LMNA | |
| SCHEMBL5071003 | 0.94 | PTGS2 (0.84) | PTGS2NR4A2MT-CO2PTGS1LMNA | |
| SCHEMBL13772645 | 0.92 | PTGS2 (0.85) | PTGS2NR4A2MT-CO2PTGS1LMNA | |
| SCHEMBL5071874 | 0.89 | PTGS2 (0.80) | PTGS2NR4A2MT-CO2PTGS1LMNA | |
| Parecoxib SCHEMBL9529 | 0.89 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1LMNA | |
| SCHEMBL28646416 | 0.89 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1LMNA | |
| Parecoxib SCHEMBL29561416 | 0.89 | PTGS2 (1.00) | PTGS2NR4A2MT-CO2PTGS1LMNA | |
| Parecoxib SCHEMBL5709079 | 0.88 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1LMNA | |
| Parecoxib SCHEMBL117193 | 0.88 | PTGS2 (0.98) | PTGS2NR4A2MT-CO2PTGS1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1288206-B1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | SEARLE LLC (US) | 2008-09-17 | — | — | EP | claimed |
| US-6815460-B2 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2004-11-09 | — | — | US | claimed |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2003-04-10 | — | — | US | claimed |
| EP-1288206-A1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | G.D. SEARLE & CO. (US) | 2003-03-05 | — | — | EP | claimed |
| JP-3382624-B2 | — | — | 2003-03-04 | — | — | JP | claimed |
| US-6436967-B1 | PREFERENTIAL CYCLOOXYGENASE INHIBITORS USED AS INJECTABLE ANALGESIC AND ANTIINFLAMMATORY AGENTS HAVING REDUCED SIDE EFFECTS; ACYLATION | PHARMACIA CORPORATION | 2002-08-20 | — | — | US | claimed |
| JP-2000509029-A | — | — | 2000-07-18 | — | — | JP | claimed |
| EP-0892791-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-27 | — | — | EP | claimed |
| WO-1997038986-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-23 | — | — | WO | claimed |
| EP-3509604-B1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TUFTS COLLEGE (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2024-08-22 | — | — | US | disclosed |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | TRUSTEES OF TUFTS COLLEGE (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | TRUSTEES OF TUFTS COLLEGE | 2023-12-07 | — | — | US | disclosed |
| WO-2004045509-A2 | METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY | PHARMACIA CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PHARMACIA CORPORATION | 2003-04-10 | — | — | US | disclosed |
| EP-1288206-A1 | Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors | G.D. SEARLE & CO. (US) | 2003-03-05 | — | — | EP | disclosed |
| US-6436967-B1 | PREFERENTIAL CYCLOOXYGENASE INHIBITORS USED AS INJECTABLE ANALGESIC AND ANTIINFLAMMATORY AGENTS HAVING REDUCED SIDE EFFECTS; ACYLATION | PHARMACIA CORPORATION | 2002-08-20 | — | — | US | disclosed |
| EP-0892791-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038986-A1 | SUBSTITUTED BENZENESULFONAMIDE DERIVATIVES AS PRODRUGS OF COX-2 INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277659-A1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885NR4A2 1592/4885MT-CO2 4791/4885 |
| US-12478609-B2 | Combination therapies using immuno-DASH inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885NR4A2 1592/4885MT-CO2 4791/4885 |
| US-20230390241-A1 | DASH INHIBITORS, AND USES RELATED THERETO | CD2BP2, PCNA, CD2 | PTGS2 2358/4885NR4A2 3600/4885MT-CO2 4828/4885 |
| US-20030069287-A1 | Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors | PTGS2, PTGES2, PTGES | PTGS2 1/4885NR4A2 978/4885MT-CO2 2100/4885 |
| US-11957657-B2 | Combination therapies using immuno-dash inhibitors and PGE2 antagonists | HPGDS, PTGIS, PTGDR2 | PTGS2 19/4885NR4A2 1592/4885MT-CO2 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.